Cancer Biomarkers Market Size & Share, by Profiling Technology (Omics Technologies, Imaging Technologies, Immunoassays); Biomolecule (Genetic, Protein, Glyco Biomarkers); Cancer Type (Breast, Lung, Prostate, Colorectal, Stomach, Other Cancers); Application (Diagnostics, Drug Discovery & Development Prognosis, Risk Assessment) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4552
  • Published Date: Feb 24, 2023
  • Report Format: PDF, PPT

Companies Dominating the Cancer Biomarkers Landscape

top-features-companies
    • INOVIQ
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bio-Rad Laboratories, Inc.
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • Merck KGaA
    • CENTOGENE GmbH
    • PerkinElmer Inc.
    • Siemens Healthcare GmbH
    • F. Hoffmann-La Roche Ltd
    • Bristol Myers Squibb Company (BMS)

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Bio-Rad Laboratories, Inc. launched Bio-Plex Pro Human Cytokine Screening Panel, the first validated high-performance multiplex assay. The panel can detect and calculate 48 different analytes associated with heart disease, allergy, cancer, autoimmunity, and others.

  • F. Hoffmann-La Roche Ltd’s VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, has been approved by the FDA and is designed to help identify patients with epithelial ovarian cancer (EOC) who are suitable for treatment with ELAHERE (mirvetuximab soravtansine-gynx). The results of this test will allow clinicians to make better treatment decisions for patients with ovarian cancer.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4552
  • Published Date: Feb 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of cancer, elevating R & D activities and investments, rising use of biomarkers in the medical sector are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 14% over the forecast period, i.e., 2023-2033.

The dearth of reimbursement policies for biomarker testing, and requirement of hefty capital investment for research and development activities are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are INOVIQ, Bio-Rad Laboratories, Inc., Abbott Laboratories, Becton, Dickinson and Company, Merck KGaA, CENTOGENE GmbH, PerkinElmer Inc., Siemens Healthcare GmbH, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by profiling technology, biomolecule, cancer type, application, and by region.

The breast cancer segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying